Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at tumor cells · developed by Iovance Biotherapeutics
Lifileucel (AMTAGVI) is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy. Tumor-derived T cells are isolated from a patient's tumor sample, expanded ex vivo with interleukin-2, and reinfused to recognize and kill the patient's tumor cells.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 14, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05727904 | Phase 3 | Metastatic Melanoma | Recruiting | IOVA |
| NCT07288073 | Phase 2 | Cutaneous Squamous Cell Carcinoma | Recruiting | IOVA |
| NCT06481592 | Phase 2 | Endometrial Cancer | Recruiting | IOVA |
| NCT04111510 | Phase 2 | Metastatic Triple Negative Breast Cancer | Completed | IOVA |
| NCT03645928 | Phase 2 | Metastatic Melanoma | Terminated | IOVA |
| NCT03449108 | Phase 2 | Bone Sarcoma | Active not recruiting | IOVA |
| NCT03108495 | Phase 2 | Cervical Carcinoma | Terminated | IOVA |
| NCT06190249 | Phase 1 | Stage IIIB Melanoma | Withdrawn | IOVA |
| NCT06566092 | Phase 1 | Soft Tissue Sarcoma | Active not recruiting | IOVA |
| NCT05640193 | Phase 1 | Metastatic Melanoma | Active not recruiting | IOVA |
| NCT05607095 | Phase 1 | Uveal Melanoma | Recruiting | IOVA |
| NCT07700121 | Early Phase 1 | Unresectable or Metastatic Melanoma | Not yet recruiting | IOVA |
| NCT05398640 | N/A | Unresectable Melanoma | Available | IOVA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of BoneMalignancy in Giant Cell Tumor of BoneMalignant Solid NeoplasmOvarian CarcinosarcomaPlatinum-Resistant Ovarian CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent OsteosarcomaRecurrent Ovarian CarcinomaRefractory OsteosarcomaSoft Tissue SarcomaThyroid Gland Anaplastic CarcinomaThyroid Gland Squamous Cell Carcinoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the IOVA page.
See IOVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IOVA catalysts and pipeline →